Abstract: . . .  guarantee regarding potential future sales of Diovan. In particular, management's expectations regarding commercialization of Diovan could be affected by, among other things, additional analysis of Diovan clinical data; new clinical data; unexpected clinical trial results; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent . . .
. . .  john.gilardi@group.novartis.com 1/1 MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Diovan receives approval in Sweden to treat high-risk heart attack patients First-in-class approval solidifies already established cardio-protective benefits of leading high blood pressure . . .
. . .  toward, secures on the forefront, look forward to, is pursuing, is expected, or similar expressions, or by express or implied discussions regarding potential new indications or labeling and marketing approvals for Diovan or regarding potential future sales of Diovan. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results . . .
. . .  failure in patients who cannot tolerate ACE inhibitors. Additional approvals are pending in the European Union for Diovan for the treatment of heart failure. This new indication for Diovan in Sweden is for the treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular dysfunction after a recent myocardial infarction ( heart attack ) .  . . .
. . .  patients who cannot tolerate ACE inhibitors. Additional approvals are pending in the European Union for Diovan for the treatment of heart failure. This new indication for Diovan in Sweden is for the treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular dysfunction after a recent myocardial infarction ( heart attack ) . Novartis is focused . . .
--2066,5,207,2456,10331